Evidence map›Paper›PMID 37928426›Full record

ArticleJournal of Cancer2023

Prognosis, Immune Microenvironment Infiltration and Immunotherapy Response in Clear Cell Renal Cell Carcinoma Based on Cuproptosis-related Immune Checkpoint Gene Signature.

Gang Liu, Feifei Li, Yuntian Ge, Yaxing Shi, Fang Ren, Liancheng Zhu

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of Cancer, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.5field-weighted citation impact, top 28% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 2 citations in OpenAlex.

  1. Targeting cuproplasia and cuproptosis in cancer.Nature reviews. Clinical oncology · 2024
    Review
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 2 institutions in 1 country.

Gang LiuDepartment of Urology, Shengjing Hospital of China Medical University, Shenyang 110004, Liaoning, China.
Feifei LiDepartment of Gynecology, Shandong Provincial Hospital Affiliated to Shandong First Medical University, Jinan, China.
Yuntian GeDepartment of Urology, Shengjing Hospital of China Medical University, Shenyang 110004, Liaoning, China.
Yaxing ShiDepartment of Urology, Shengjing Hospital of China Medical University, Shenyang 110004, Liaoning, China.
Fang RenDepartment of Obstetrics and Gynecology, Shengjing Hospital of China Medical University, Shenyang, Liaoning, China.
Liancheng ZhuDepartment of Obstetrics and Gynecology, Shengjing Hospital of China Medical University, Shenyang, Liaoning, China.
China Medical University · CNShandong First Medical University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

clear cell renal cell carcinomacuproptosisimmune checkpointimmune microenvironmentimmune therapy.prognosis

Identifiers

PMID37928426
PMCPMC10622984
OpenAlexW4387739895

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.